Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome".
Press Release Mar 16 2026
Filed with NSE · · 4 pages · English
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 14 2026
- Press Release Mar 13 2026
- Press Release Mar 12 2026
- Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
- Press Release Feb 28 2026
Later from Zydus Lifesciences
- Press Release Mar 17 2026
- Press Release Mar 18 2026
- AeroDel signs exclusive licensing arrangement with Zydus for launching Aerolife Mini™, India's First Foldable, 'Always Attached' pMDI Enhancer
- Press Release Mar 19 2026
- Zydus Lifesciences Limited Press Release Mar 21 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences